San Diego, CA USA (UroToday.com) With prostate cancer being the most common malignancy affecting men and various treatment options available such as surgery, radiotherapy, and even active surveillance, it is important to evaluate the functional outcome effects of therapies in the context of a diverse U.S. population. In this study from Vanderbilt University, the authors sought to evaluate outcomes following treatment for prostate cancer amongst African American (AA), Hispanic (H) and White (W) populations.
In this prospective cohort study, 3,708 men across the U.S. using SEER registries were followed after Radical prostatectomy, External Beam Radioatherapy and Active Surveillance treatments for localized prostate cancer using the self-reported EPIC-26 questionnaire at baseline, 6 months and 12 months. In the end, data was gathered from 2,338 men: 78.5% White, 13.9% African American, and 7.3% Hispanic.
The authors found that post-treatment urinary outcomes of irritability and incontinence, bowel irritability and sexual function did not vary dramatically based by race. Also, there were no statistically significant differences in bother with respect to urinary, bowel and sexual function based on race/ethnicity. Next, different demographic and social factors such as T-stage, PSA, education, marital status, etc. were evaluated in a model to test the predictive function of urinary incontinence at one year. As expected, race failed to show any predictive function, however, primary treatment selection and baseline function were shown to be the most predictive of urinary function.
The underlying hypothesis for the study stemmed from the 2004 PCOS report that African American men had improved recovery of urinary and sexual function compared to Whites after prostatectomy or radiotherapy. The author provides that in this prospective study of a large population-based cohort encompassed a larger patient sample, inclusion of an active surveillance arm and a more updated robotic experience that could explain the lack of racial differences in outcomes in this study.
Presented By: Mark Tyson, MD
Written By: Blanca Morales, Department of Urology, University of California, Irvine at the 2016 AUA Annual Meeting - May 6 - 10, 2016 – San Diego, California, USA